It said that a sale to a strategic buyer was imminent.
Xellia is an Oslo-based global developer, manufacturer and supplier of pharmaceutical ingredients.
The business employs over 800 staff and serves over 600 customers in 60 countries. Its clients include a range of national, multinational and global pharmaceutical companies. Xellia currently operates from four production sites – in Denmark, Hungary, Norway and China – and has sales offices in Budapest, Chicago, Copenhagen, New Jersey, Oslo, Shanghai, Singapore, Tokyo and Zagreb.
Xellia was created in 2008 when 3i backed the €258m buyout from NYSE-listed Alpharma.
Copyright © 2013 AltAssets